Abstract
Bacterial meningitis in adults is a severe disease with high fatality and morbidity rates. Experimental studies have shown that the inflammatory response in the subarachnoid space is associated with an unfavourable outcome. In these experiments, corticosteroids, and in particular dexamethasone, were able to reduce the inflammatory cascades in the subarachnoid space. The use of corticosteroids as adjunctive therapy in adults with bacterial meningitis has been evaluated in six studies, performed over a time period of 40 years. Most studies on adjunctive dexamethasone therapy in adults with bacterial meningitis were limited by methodological flaws. In 2002, a study with sufficient statistical power to show significant differences was published. This European Dexamethasone Study showed that adjunctive dexamethasone therapy reduced the rate of unfavourable outcomes in adults with bacterial meningitis from 25% to 15%. In this study, adjunctive treatment with dexamethasone was given before or with the first dose of antibacterials, without serious adverse effects. A quantitative review showed a consistent beneficial effect of dexamethasone on mortality and a borderline statistical beneficial effect on neurological sequelae. On the basis of the available evidence, adjunctive dexamethasone therapy should be initiated before or with the first dose of antibacterials and continued for 4 days in all adults with suspected or proven bacterial meningitis, regardless of bacterial aetiology. In patients with both meningitis and septic shock, dexamethasone therapy cannot be unequivocally recommended, but the use of lower doses seems reasonable at present. Since prompt use of dexamethasone and appropriate antibacterials improves the prognosis of adults with bacterial meningitis, hospitals will require protocols to include dexamethasone with the initial antibacterial therapy.
Similar content being viewed by others
References
Swartz MN. Bacterial meningitis: a view of the past 90 years. N Engl J Med 2004; 351: 1826–8
van de Beek D, de Gans J, Spanjaard L, et al. Clinical features and prognostic factors in adults with bacterial meningitis. N Engl J Med 2004; 351: 1849–59
Koedel U, Scheid WM, Pfister HW. Pathogenesis and pathophysiology of pneumococcal meningitis. Lancet Infect Dis 2002; 2: 721–36
Scheld WM, Dacey RG, Winn HR, et al. Cerebrospinal fluid outflow resistance in rabbits with experimental meningitis: alterations with penicillin and methylprednisolone. J Clin Invest 1980; 66: 243–53
Tauber MG, Khayam-Bashi H, Sande MA. Effects of ampicillin and corticosteroids on brain water content, cerebrospinal fluid pressure, and cerebrospinal fluid lactate levels in experimental pneumococcal meningitis. J Infect Dis 1985; 151: 528–34
van de Beek D, de Gans J, McIntyre P, et al. Corticosteroids in acute bacterial meningitis. The Cochrane Library, issue 3. Chichester, UK: John Wiley & Sons Ltd, 2003
de Gans J, van de Beek D. Dexamethasone in adults with bacterial meningitis. N Engl J Med 2002; 347: 1549–56
Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004; 39: 1267–84
van de Beek D, de Gans J, Tunkel AR, et al. Community-acquired bacterial meningitis. N Engl J Med 2006; 354: 46–55
Schuchat A, Robinson K, Wenger JD, et al. Bacterial meningitis in the United States in 1995. Active Surveillance Team. N Engl J Med 1997; 337: 970–6
Durand ML, Calderwood SB, Weber DJ, et al. Acute bacterial meningitis in adults: a review of 493 episodes. N Engl J Med 1993; 328: 21–8
Peltola H. Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Rev 2000; 13: 302–17
Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003; 348: 1737–46
Swiatlo E, Ware D. Novel vaccine strategies with protein antigens of Streptococcus pneumoniae. FEMS Immunol Med Microbiol 2003; 38: 1–7
Trotter CL, Ramsay ME, Kaczmarski EB. Meningococcal serogroup C vaccination in England and Wales: coverage and initial impact of the campaign. Commun Dis Public Health 2002; 5: 220–5
Weite R, van den Dobbelsteen G, Bos JM, et al. Economic evaluation of meningococcal serogroup C conjugate vaccination programmes in The Netherlands and its impact on decision-making. Vaccine 2004; 23: 470–9
Snape MD, Pollard AJ. Meningococcal polysaccharide-protein conjugate vaccines. Lancet Infect Dis 2005; 5: 21–30
Weisfelt M, van de Beek D, Spanjaard L, et al. Clinical features, complications, and outcome in adults with pneumococcal meningitis: a prospective case series. Lancet Neurol 2006; 5(2): 123–9
Kastenbauer S, Pfister HW. Pneumococcal meningitis in adults: spectrum of complications and prognostic factors in a series of 87 cases. Brain 2003; 126: 1015–25
Tunkel AR. Bacterial meningitis. Philadelphia (PA): Lippincott Williams & Wilkins, 2001
van de Beek D, de Gans J. Adjunctive corticosteroids in adults with bacterial meningitis. Curr Infect Dis Rep 2005; 7: 285–91
Appelbaum PC. Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clin Infect Dis 1992; 15: 77–83
Whitney CG, Farley MM, Hadler J, et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med 2000; 343: 1917–24
Saez-Llorens X, McCracken GH. Antimicrobial and anti-inflammatory treatment of bacterial meningitis. Infect Dis Clin North America 2000; 13: 619–36
Aronin SI, Peduzzi P, Quagliarello VJ. Community-acquired bacterial meningitis: risk stratification for adverse clinical outcome and effect of antibiotic timing. Ann Intern Med 1998; 129: 862–9
Proulx N, Frechette D, Toye B, et al. Delays in the administration of antibiotics are associated with mortality from adult acute bacterial meningitis. QJM 2005; 98: 291–8
Attia J, Hatala R, Cook DJ, et al. The rational clinical examination: does this adult patient have acute meningitis? JAMA 1999; 282: 175–81
van de Beek D, Schmand B, de Gans J, et al. Cognitive impairment in adults with good recovery after bacterial meningitis. J Infect Dis 2002; 186: 1047–52
Weisfelt M, van de Beek D, Hoogman M, et al. Cognitive outcome in adults with moderate disability after pneumococcal meningitis. J Infect. Epub 2005 Oct 6
Schmidt H, Heimann B, Djukic M, et al. Neuropsychological sequelae of bacterial and viral meningitis. Brain 2005 Dec 19
Nau R, Brück W. Neuronal injury in bacterial meningitis: mechanisms and implications for therapy. Trends Neurosc 2002; 25: 38–45
Mustafa MM, Ramilo O, Mertsola J, et al. Modulation of inflammation and cachectin activity in relation to treatment of experimental Haemophilus influenzae type b meningitis. J Infect Dis 1989; 160: 818–25
Weisfelt M, de Gans J, van der Poll T, et al. Pneumococcal meningitis in adults: new approaches to management and prevention. Lancet Neurol. In press
Czock D, Frieder Keller F, Rasche FM, et al. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokin 2005; 44: 61–98
Balis FM, Lester CM, Chrousos GP, et al. Differences in cerebrospinal fluid penetration of corticosteroids: possible relationship to the prevention of meningeal leukemia. J Clin Oncol 1987; 5: 202–7
Lutsar I, Friedland IR, Jafri HS, et al. Factors influencing the anti-inflammatory effect of dexamethasone therapy in experimental pneumococcal meningitis. J Antimicrob Chemother 2003; 52: 651–5
Nau R, Wellmer A, Soto A, et al. Rifampin reduces early mortality in experimental Streptococcus pneumoniae meningitis. J Infect Dis 1999; 179: 1557–60
Mattie H, Stuertz K, Nau R, et al. Pharmacodynamics of antibiotics with respect to bacterial killing of and release of lipoteichoic acid by Streptococcus pneumoniae. J Antimicrob Chemother 2005; 56: 154–9
McIntyre PB, Berkey CS, King SM, et al. Dexamethasone as adjunctive therapy in bacterial meningitis. A meta-analysis of randomized clinical trials since 1988. JAMA 1997; 278: 925–31
Baraff LJ, Lee SI, Schriger DL. Outcomes of bacterial meningitis in children: a meta-analysis. Pediatr Infect Dis J 1993; 12: 389–94
Molyneux EM, Walsh AL, Forsyth H, et al. Dexamethasone treatment in childhood bacterial meningitis in Malawi: a randomised controlled trial. Lancet 2002; 360: 211–8
Bennett IL, Finland M, Hamburger M, et al. The effectiveness of hydrocortisone in the management of severe infections. JAMA 1963; 183: 462–5
Girgis NI, Farid Z, Mikhail IA, et al. Dexamethasone treatment for bacterial meningitis in children and adults. Pediatr Infect Dis J 1989; 8: 848–51
Gijwani D, Kumhar MR, Singh VB, et al. Dexamethasone therapy for bacterial meningitis in adults: a double blind placebo control study. Neurol India 2002; 50: 63–7
Bhaumik S, Behari M. Role of dexamethasone as adjunctive therapy in acute bacterial meningitis in adults. Neurol India 1998; 46: 225–8
Thomas R, Le Tulzo Y, Bouget J, et al. Trial of dexamethasone treatment for severe bacterial meningitis in adults. Adult Meningitis Steroid Group. Intensive Care Med 1999; 25: 475–80
van de Beek D, de Gans J, McIntyre P, et al. Steroids in adults with bacterial meningitis: a systematic review. Lancet Infect Dis 2004; 4: 139–43
van de Beek D, de Gans J. Dexamethasone and pneumococcal meningitis. Ann Intern Med 2004; 141: 327
Weisfelt M, van de Beek D, de Gans J. Dexamethasone treatment in adults with pneumococcal meningitis: risk factors for death. Eur J Clin Microb Infect Dis. Epub 2006 Feb 10
Weisfelt M, van de Beek D, de Haan RJ, de Gans J. Dexamethasone and prognostic factors in adults with bacterial meningitis. J Neurol. Epub 2005 Nov 24
Syrogiannopoulos GA, Lourida AN, Theodoridou MC, et al. Dexamethasone therapy for bacterial meningitis in children: 2-versus 4-day regimen. J Infect Dis 1994; 169: 853–8
Spanos A, Harrell FE, Durack DT. Differential diagnosis of acute meningitis: an analysis of the predictive value of initial observations. JAMA 1989; 262: 2700–7
Tunkel AR, Scheld WM. Corticosteroids for everyone with meningitis? N Engl J Med 2002; 347: 1613–5
Davis LE, Greenlee JE. Pneumococcal meningitis: antibiotics essential but insufficient. Brain 2003; 126: 1013–4
Cohen J. Management of bacterial meningitis in adults. BMJ 2003; 326: 996–7
Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288: 862–71
Van de Beek D, De Gans J, Spanjaard L, et al. Antibiotic guidelines and antibiotic use in adult bacterial meningitis in The Netherlands. J Antimicrob Chemother 2002; 49: 661–6
Cronin L, Cook DJ, Carlet J, et al. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med 1995; 23: 1430–9
Annane D, Bellissant E, Bollaert P, et al. Corticosteroids for treating severe sepsis and septic shock. The Cochrane Library, issue 1. Chichester, UK: John Wiley & Sons Ltd, 2004
Cabellos C, Martinez-Lacasa J, Tubau F, et al. Evaluation of combined ceftriaxone and dexamethasone therapy in experimental cephalosporin-resistant pneumococcal meningitis. J Antimicrob Chemoth 2000; 45: 315–20
Klugman KP, Friedland IR, Bradley JS. Bactericidal activity against cephalosporin-resistant Streptococcus pneumoniae in cerebrospinal fluid of children with acute bacterial meningitis. Antimicrob Agents Chemother 1995; 39: 1988–92
Viladrich PF, Gudiol F, Linares J, et al. Evaluation of vancomycin for therapy of adult pneumococcal meningitis. Antimicrob Agents Chemother 1991; 35: 2467–72
Leib SL, Heimgartner C, Bifrare YD, et al. Dexamethasone aggravates hippocampal apoptosis and learning deficiency in pneumococcal meningitis in infant rats. Pediatr Res 2003; 54: 353–7
Sapolsky RM, Pulsinelli WA. Glucocorticoids potentiate ischemic injury to neurons: therapeutic implications. Science 1985; 229: 1397–400
Jiang X, Mu D, Manabat C, et al. Differential vulnerability of immature murine neurons to oxygen-glucose deprivation. Exp Neurol 2004; 190: 224–32
Kastenbauer S, Koedel U, Weih F, et al. Protective role of NF-kappaB1 (p50) in experimental pneumococcal meningitis. Eur J Pharmacol 2004; 498: 315–8
Bifrare YD, Kummer J, Joss P, et al. Brain-derived neurotrophic factor protects against multiple forms of brain injury in bacterial meningitis. J Infect Dis 2005; 191: 40–5
Lin MT, Albertson TE. Genomic polymorphisms in sepsis. Crit Care Med 2004; 32: 569–79
Cariou A, Chiche JD, Carpentier J, et al. The era of genomics: impact on sepsis clinical trial design. Crit Care Med 2002: 30; S341–8
Cohen J. The immunopathogenesis of sepsis. Nature 2002; 6917: 885–91
Emonts M, Hazelzet JA, De Groot R, et al. Host genetic determinants of Neisseria meningitidis infections. Lancet Infect Dis 2003; 3: 565–77
Holmes CL, Russell JA, Walley KR. Genetic polymorphisms in sepsis and septic shock. Chest 2003; 124: 1103–15
Schroder NW, Schumann RR. Single nucleotide polymorphisms of toll-like receptors and susceptibility to infectious disease. Lancet Infect Dis 2005; 5: 156–64
Nieters A, Brems S, Becker N. Cross-sectional study on cytokine polymorphisms, cytokine production after T-cell stimulation and clinical parameters in a random sample of a German population. Hum Genetics 2001; 108: 241–8
Kwiatkowski D. Science, medicine and the future: susceptibility to infection. BMJ 2000; 321: 1061–5
Levi M, van der Poll T, Buller HR. Bidirectional relation between inflammation and coagulation. Circulation 2004; 109: 2698–704
Acknowledgements
We are indebted to Dr Arie van der Ende of The Netherlands Reference Laboratory for Bacterial Meningitis for providing figure 1. Dr van de Beek received a research grant from the Meningitis Research Foundation UK. The authors have no potential conflicts of interest that that are relevant to the contents of the manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
van de Beek, D., de Gans, J. Dexamethasone in Adults with Community-Acquired Bacterial Meningitis. Drugs 66, 415–427 (2006). https://doi.org/10.2165/00003495-200666040-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-200666040-00002